Imagen de Portada

Topical dobesilate eye drops for ophthalmic primary pterygium

Guardado en:
Publicado en:BMJ Case Reports vol. 2012 (Sep 2025), p. bcr1220115449
Autor principal: Cuevas, Pedro
Otros Autores: Outeiriño, Luis A, Angulo, Javier, Giménez-Gallego, Guillermo
Publicado:
BMJ Publishing Group LTD
Materias:
Diabetes
Vascular endothelial growth factor
Neutrophils
Fibroblasts
Stem cells
Cornea
Angiogenesis
Cytokines
Acceso en línea:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:Selective inhibition of fibroblast growth factor and vascular endothelial growth factor signalling pathways is effective in causing regression of pterygia. Prompt regression of fibrovascular mass and conjunctival angiogenesis was documented 2 weeks after topical administration of dobesilate eye drops twice daily. At 3-month follow-up, no recurrence was seen and no ocular irritation and burning were noted. The authors believe that this is the first known successful use of topical dobesilate in primary pterygium.
ISSN:1757-790X
DOI:10.1136/bcr.12.2011.5449
Fuente:Health & Medical Collection